Like Vium, Inc.

closed 7/28/2020 via BusinessWire

Recursion Pharmaceuticals, Inc., acquired Vium, Inc.

synopsis: Recursion, a digital biology™ company leading in the industrialization of drug discovery, has announced its acquisition of Vium, a digital vivarium™ company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively collect and derive insights from digital biomarkers in preclinical in vivo research.
buyer: Recursion Pharmaceuticals, Inc.
Recursion is a digital biology company industrializing drug discovery. Recursion does this by combining automation, AI, machine learning, in vivo validation capabilities and a highly cross-functional team to discover novel medicines that expand our collective understanding of biology. "
target: Vium, Inc.
Vium is the first company to create a fully digital end to end Digital Vivarium® platform which is transforming in vivo research. The Vium Digital Vivarium, Vium Cloud, and online Research Suite empower scientists to optimize advances in bioengineered research models in ways previously not possible.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/23/2020 via BusinessWire

Curi Bio, acquired Dana Solutions

synopsis: Curi Bio has acquired Dana Solutions, a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays. They offer state-of-the-art AI products for drug screening, toxicity testing, and quality control.
buyer: Curi Bio
Curi Bio provides a seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines. "
target: Dana Solutions
Dana Solutions is a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays. They offer state-of-the-art AI products for drug screening, toxicity testing, and quality control.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/13/2018 via BusinessWire

Certara, acquired Pirana Software

synopsis: Certara, the global leader in model-informed drug development, regulatory science, market access and real-world evidence solutions, announced that it has acquired Pirana, a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
buyer parent: Arsenal Capital Partners
buyer: Certara
Certara enables superior drug development and patient care decision-making through model-informed drug development, regulatory science, real-world evidence solutions and knowledge integration. "
target: Pirana Software
Pirana is a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/27/2013 via PR Newswire

Temis Text Intelligence, acquired i3 Analytics

synopsis: TEMIS, the leading provider of Semantic Content Enrichment solutions for the Enterprise, announced that they have acquired the US-based i3 Analytics. i3 Analytics provides the award-winning Biopharma Navigator, a Software-as-a-Service platform that charts the biopharma landscape based on Life Sciences open data.
buyer: Temis Text Intelligence
In order to develop and market innovative Text Mining Solutions, TEMIS was founded in September 2000 by a team of managers, researchers and consultants from IBM. This skilled team had earlier developed and distributed IBM Text Mining solutions worldwide "
target: i3 Analytics
i3 Analytics is a provider of advanced data analytics and visualization technologies. Their Biopharma Navigator is an analytics tool that allow users to map clinical trials landscapes, scan the horizon for the latest news, and stay current on what researchers are doing.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/17/2012 via PR Newswire

Accelrys Software Inc., purchased Hit Explorer Operating System (HEOS) from SCYNEXIS, Inc.

synopsis: Accelrys, Inc. announced that it has purchased the Web-based Hit Explorer Operating System (HEOS) from SCYNEXIS, Inc. HEOS enables more efficient and streamlined drug discovery collaborations, particularly for organizations leveraging academic departments, research institutes and contract research organizations in externalized R&D projects.
buyer: Accelrys Software Inc. (ACCL:$166.25)
Accelrys, Inc. is a leading scientific enterprise R&D software and services company that supports industries and organizations that rely on scientific innovation to differentiate themselves. Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists. "
seller: SCYNEXIS, Inc.
HEOS® is a comprehensive web-based drug research information management software platform that supports geographically-distributed scientists and facilitates collaboration. It is heavily used by users around the world including large pharmaceutical companies and biotechnology companies.
price ($mm)
$4.50
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/15/2008 via PR Newswire

United BioSource Corporation, acquired Envision Pharma, Inc.

synopsis: United BioSource Corporation acquired Envision Pharma, a leading scientific communications and technology company. With a focus on the pharmaceutical and biotechnology industry, Envision integrates scientific communication services and targeted software applications.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Envision Pharma, Inc.
Envision Pharma is an innovative scientific communications and technology company providing commercially focused, strategically driven scientific and technology solutions to the pharmaceutical, biotechnology and device industries.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/17/2019 via Company Press Release

Nordic Capital, will acquire Aris Global LLC

synopsis: Nordic Capital, a leading private equity investor in the Nordic region, will be acquiring ArisGlobal, a visionary technology company that has successfully developed a next-generation platform that uses advanced cognitive computing and machine learning to automate all core functions of drug safety, regulatory compliance and medical affairs.
buyer: Nordic Capital
Nordic Capital is a leading private equity investor in the Nordic region with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. "
target: Aris Global LLC
ArisGlobal is transforming the way most successful life sciences companies develop breakthroughs. Their end-to-end drug development technology platform, LifeSphere, integrates their proprietary Nava cognitive computing engine to automate all core functions of the drug development lifecycle.
price ($mm)
$700
rev ($mm)
$100
EBITDA ($mm)
EV / rev
7.0x
EV / EBITDA
announced 2/14/2006 via BusinessWire

Secured Financial Network, Inc., will acquire HEB LLC

synopsis: Secured Financial Network Inc. announced the signing of a binding letter of intent to acquire 100% of HEB LLC, with assets of $16,744,475 and liabilities of $4,095,471, for cash and stock.
buyer: Secured Financial Network, Inc.
Secured Financial Network is focused on short-term high margin financial investments. Sometimes called “Bridge or Opportunity Financing”, SFNL focuses on these types of financial investments with a focus on limited downside risk. "
target: HEB LLC
HEB has an interest in Veriscrip and controlling interest in Wound Care Innovations LLC. Veriscrip is an application services provider of real-time electronic prescribing and prescription tracking systems for healthcare professionals and regulatory agencies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/20/2019 via BNC Analysis

Monterro, acquired Viedoc

synopsis: Monterro, the leading B2B software investor in the Nordics, has acquired a majority stake in Viedoc, a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently.
buyer: Monterro
Sweden-based Monterro is the leading B2B software investor in the Nordics, with a mission to turn software companies into market leaders. With operational experience from successfully developing and running companies, Monterro actively supports its portfolio companies in all aspects of growth. "
target: Viedoc
Viedoc is a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently. Their powerful EDC system has been used in over 2000 trials in more than 75 countries in all therapeutic areas and clinical phases.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/24/2019 via BNC Analysis

TrialScope, acquired Clinical Trial Connect, LLC

synopsis: TrialScope has acquired Clinical Trial Connect, a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. As part of the acquisition, founder Mike Wenger will share his technological expertise as part of the TrialScope team.
buyer: TrialScope
TrialScope is the global leader in clinical trial transparency and compliance. TrialScope's tools and systems enable their customers to improve their clinical trial process, mitigate registry and lifecycle risk, and ultimately achieve greater business success. "
target: Clinical Trial Connect, LLC
Clinical Trial Connect is a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. Clinical Trial Connect was founded by Mike Wenger, who developed his own algorithm for matching patients to clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/28/2019 via BNC Analysis

JLL Partners, Water Street Healthcare Partners, acquired THREAD Research

synopsis: Water Street Healthcare Partners and JLL Partners have acquired Orange County, California-based THREAD, a provider of technology that enables virtual research approaches to modernize clinical studies and registries.
buyer: JLL Partners
buyer: Water Street Healthcare Partners
JLL Partners is a middle-market private equity firm with a 30-year track record of building and transforming businesses. Water Street is a strategic investor focused exclusively on healthcare. The firm has a strong record of building market-leading companies across key growth sectors in healthcare. "
target: THREAD Research
THREAD is a virtual research platform used by biopharma, CROs, non-profit researchers, and life science organizations to capture global clinical study data in between, as well as during and instead of clinic visits.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/17/2019 via GlobeNewswire

Anju Software, will acquire OmniComm Systems, Inc.

synopsis: Anju Software, a leading provider of comprehensive software solutions to the life sciences industry, will be acquiring OmniComm, a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services.
buyer parent: ABRY Partners, LLC
buyer: Anju Software
Anju Software, Inc. is a leading provider of comprehensive software solutions to the life sciences industry that provides an integrated platform spanning clinical operations, medical affairs, and commercial divisions, including integrated data intelligence. "
target: OmniComm Systems, Inc. (OTCPK:OMCM:$24.62)
OmniComm is a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations, and other clinical trial sponsors.
price ($mm)[EV]
$72 [$81]
rev ($mm)
$25
EBITDA ($mm)
$2
EV / rev
3.4x
EV / EBITDA
46.2x
announced 6/12/2019 via BusinessWire

Dassault Systemes, will acquire Medidata

synopsis: Dassault Systèmes, a provider of solutions that transform the way products are designed, provided and supported, will be acquiring Medidata, a provider of a platform for clinical development, commercial, and real-world data.
buyer: Dassault Systemes (ENXTPA:DSY:$5,061.43)
Based in France, Dassault Systèmes provides clients with virtual universes to imagine sustainable innovations. Its solutions transform the way products are designed, produced, and supported. They foster social innovation, expanding possibilities for the virtual world to improve the real world. "
target: Medidata (MDSO:$660.00)
Medidata is leading the digital transformation of life science, with a platform for clinical development, commercial, and real-world data. Powered by artificial intelligence, Medidata helps accelerate value, minimize risk and optimize outcomes.
price ($mm)[EV]
$5,825 [$5,822]
rev ($mm)
$660
EBITDA ($mm)
$81
EV / rev
8.8x
EV / EBITDA
72.2x
closed 4/10/2019 via BNC Analysis

TriNetX, acquired Custodix N.V.

synopsis: TriNetX has acquired Custodix, a Belgian-based provider of clinical trial patient recruitment solutions. TriNetX is a global health research network that has revolutionised clinical research. Custodix is a provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance.
buyer: TriNetX
TriNetX is the global health research network enabling healthcare organizations, biopharma and CROs to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. "
target: Custodix N.V.
Custodix is a Belgian provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance with European and US data protection legislation and security best practices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/17/2018 via Company Press Release

Oracle Corporation, will acquire GoBalto

synopsis: Oracle announced that it has entered into an agreement to acquire goBalto, which delivers leading cloud solutions to accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials.
buyer: Oracle Corporation (ORCL:$39,766.00)
Oracle is a computer technology corporation developing and marketing computer hardware systems and enterprise software products. By eliminating complexity and simplifying IT, Oracle enables its customers to accelerate innovation and create added value for their customers. "
target: GoBalto
goBalto, Inc. is an award winning, venture backed group of industry veterans that creates simple, focused software for the global drug trial industry. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/21/2018 via BusinessWire

Anju Software, acquired Sylogent

synopsis: Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired Sylogent. Sylogent delivers cloud based state of the art software solutions and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market.
buyer parent: Providence Equity Partners Inc.
buyer: Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions. Anju was founded by professionals with deep software domain expertise and a track record of building software platforms through strategic acquisitions and organic growth. "
target: Sylogent
Sylogent delivers software and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market. They ensure the timely completion of critical information, maximize compliance goals and reduce risk management liability.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/9/2017 via Company Press Release

PRA Health Sciences, acquired Parallel 6

synopsis: HCAP Partners, a California-based mezzanine debt and private equity firm, announced that it has exited its investment in Parallel 6, Inc. (“P6”), a mobile clinical (“mClinical”) SaaS platform designed to recruit, enroll, engage and manage patients in clinical trials. P6 was sold to PRA Health Sciences, Inc.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences, Inc. is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: HCAP Partners
target: Parallel 6
Parallel 6’s technology digitally enrolls, engages and manages patients using mobile endpoints. Sponsors and clinical research organizations can connect directly with and manage patients anywhere in the world, seamlessly integrating into their daily lives.
price ($mm)
$40
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/16/2016 via BNC Analysis

DrugDev, acquired SecureConsent

synopsis: DrugDev has acquired SecureConsent, a developer of mobile e-consent software. SecureConsent replaces the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
buyer: DrugDev
DrugDev streamlines engagement among sponsors, CROs and doctors to advance the common goal of doing more trials. Through the creation of global, standardized processes DrugDev is consistently and efficiently transforming the way drug developers identify, engage and pay investigators. "
target: SecureConsent
The software products developed by Secure Consent replace the paper methods that have historically been used to secure informed consent from patients participating in drug studies with an e-consent method that uses tablets and other mobile devices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2016 via PR Newswire

BioClinica, Inc., acquired Clinverse, Inc.

synopsis: Bioclinica, Inc., a specialty trials services and technology provider, announced it has acquired Clinverse, Inc. Clinverse automates and manages the entire financial lifecycle of global clinical trials for contract research organizations and pharmaceutical companies. Its suite of products pays clinical trial sites, vendors and their subjects.
buyer: BioClinica, Inc.
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized into three business segments to deliver focused service and multifaceted technologies. "
target: Clinverse, Inc.
Clinverse, Inc. architected the industry's first automated financial management technology solution for clinical trials. Their solution standardizes clinical trial financial management for millions of financial transactions across the globe, including clinical site payments.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/17/2015 via PR Web

Aris Global LLC, acquired Medsight Solutions Inc.

synopsis: ArisGlobal®, a leading provider of Cloud solutions to life sciences companies, is pleased to announce that it has acquired Medsight Solutions, including the revolutionary integrated risk management solution, Medsight Sapphire (now known as ArisGlobal agBalance™).
buyer: Aris Global LLC
For more than 20 years, ArisGlobal has led in the development of innovative software solutions for pharmacovigilance & safety, regulatory affairs, clinical research and medical information. "
target: Medsight Solutions Inc.
Medsight Solutions Inc. is a life sciences solutions and professional services company with specialties in Clinical trial optimization, Benefit-risk assessment and Compliance monitoring.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/28/2020 via BusinessWire

Recursion Pharmaceuticals, Inc., acquired Vium, Inc.

synopsis: Recursion, a digital biology™ company leading in the industrialization of drug discovery, has announced its acquisition of Vium, a digital vivarium™ company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively collect and derive insights from digital biomarkers in preclinical in vivo research.
buyer: Recursion Pharmaceuticals, Inc.
Recursion is a digital biology company industrializing drug discovery. Recursion does this by combining automation, AI, machine learning, in vivo validation capabilities and a highly cross-functional team to discover novel medicines that expand our collective understanding of biology. "
target: Vium, Inc.
Vium is the first company to create a fully digital end to end Digital Vivarium® platform which is transforming in vivo research. The Vium Digital Vivarium, Vium Cloud, and online Research Suite empower scientists to optimize advances in bioengineered research models in ways previously not possible.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/28/2020 via BusinessWire

Recursion Pharmaceuticals, Inc., acquired Vium, Inc.

synopsis: Recursion, a digital biology™ company leading in the industrialization of drug discovery, has announced its acquisition of Vium, a digital vivarium™ company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively collect and derive insights from digital biomarkers in preclinical in vivo research.
buyer: Recursion Pharmaceuticals, Inc.
Recursion is a digital biology company industrializing drug discovery. Recursion does this by combining automation, AI, machine learning, in vivo validation capabilities and a highly cross-functional team to discover novel medicines that expand our collective understanding of biology. "
target: Vium, Inc.
Vium is the first company to create a fully digital end to end Digital Vivarium® platform which is transforming in vivo research. The Vium Digital Vivarium, Vium Cloud, and online Research Suite empower scientists to optimize advances in bioengineered research models in ways previously not possible.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/28/2020 via BusinessWire

Recursion Pharmaceuticals, Inc., acquired Vium, Inc.

synopsis: Recursion, a digital biology™ company leading in the industrialization of drug discovery, has announced its acquisition of Vium, a digital vivarium™ company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively collect and derive insights from digital biomarkers in preclinical in vivo research.
buyer: Recursion Pharmaceuticals, Inc.
Recursion is a digital biology company industrializing drug discovery. Recursion does this by combining automation, AI, machine learning, in vivo validation capabilities and a highly cross-functional team to discover novel medicines that expand our collective understanding of biology. "
target: Vium, Inc.
Vium is the first company to create a fully digital end to end Digital Vivarium® platform which is transforming in vivo research. The Vium Digital Vivarium, Vium Cloud, and online Research Suite empower scientists to optimize advances in bioengineered research models in ways previously not possible.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 1/24/2020 via GlobeNewswire

Predictive Oncology Inc., will acquire Quantitative Medicine

synopsis: Predictive Oncology Inc. , a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, is to acquire Quantitative Medicine, a biomedical analytics and computational biology company that has developed a novel, computational drug discovery platform called CoRE.
buyer: Predictive Oncology Inc. (POAI:$1.38)
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. "
target: Quantitative Medicine
Quantitative Medicine is a biomedical analytics and computational biology company that has developed a novel, computational drug discovery platform called CoRE. CoRE is designed to dramatically reduce the time, cost and financial risk of discovering new therapeutic drugs.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/15/2019 via BusinessWire

Instem, acquired Leadscope, Inc.

synopsis: Instem, a leading provider of IT solutions to the global life sciences market, announced that it has acquired Leadscope, a company that builds a chemoinformatics platform. Using Leadscope, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques.
buyer: Instem (AIM:INS:$30.83)
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide. "
target: Leadscope, Inc.
Leadscope builds a chemoinformatics platform. As a suite of tools, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques (prediction tools, scaffold generators, etc.).
price ($mm)
$4.10
rev ($mm)
$2
EBITDA ($mm)
$0
EV / rev
2.4x
EV / EBITDA
11.5x
closed 3/2/2016 via Company Press Release

C4X Discovery, acquired Adorial

synopsis: C4X Discovery, a company that aims to become the world’s most productive drug discovery and development company, has acquired Adorial, a privately held drug discovery company with a proprietary genetic technology platform for the identification of novel drug targets.
buyer: C4X Discovery (AIM:C4XD:$0.44)
C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. "
target: Adorial
Adorial's key genetic technology, Taxonomy3® is a novel in silico platform technology that utilises proprietary ground-breaking mathematical algorithms to perform complex multivariate analysis of genetic data.
price ($mm)
$2.36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/3/2012 via BusinessWire

CLC bio A/S, acquired Molegro

synopsis: CLC bio announced the acquisition of Molegro, a specialized software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity.
buyer: CLC bio A/S
CLC bio is the world's leading bioinformatics solution provider and the only one that provides both desktop and server software seamlessly integrated and optimized for best performance. The company is headquarted in Aarhus, Denmark. "
target parent: Østjysk Innovation A/S
target: Molegro
Founded in 2005, Molegro is a specialized software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/13/2012 via BusinessWire

Certara, will acquire Simcyp Limited

synopsis: Certara has announced the completion of its acquisition of UK-based Simcyp Limited. Simcyp is a leading research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations, including pediatric populations.
buyer parent: Vector Capital
buyer: Certara
Certara™ is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. "
target parent: Fusion IP plc
target: Simcyp Limited
Simcyp provides platforms for the modeling and simulation of pharmacokinetics and pharmacodynamics in virtual human populations and virtual laboratory animals (rat, dog and mouse).
price ($mm)
$32
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/3/2008 via BusinessWire

Tripos, Inc., acquired Pharsight Corporation

synopsis: Tripos International, the leading provider of drug discovery informatics products and services, today announced that it has completed the acquisition of Pharsight Corporation, a leader in software, strategic and regulatory services designed to optimize clinical drug development.
buyer parent: Vector Capital
buyer: Tripos, Inc.
Tripos combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. "
target: Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.
price ($mm)[EV]
$52 [$36]
rev ($mm)
$28
EBITDA ($mm)
$2
EV / rev
1.4x
EV / EBITDA
17.8x
closed 5/1/2006 via BusinessWire

PerkinElmer, Inc., acquired Spectral Genomics, Inc.

synopsis: PerkinElmer, Inc., a global technology leader in Health Sciences and Photonics, today announced the acquisition of the assets of Spectral Genomics, Inc., a leader in molecular karyotyping technology used to evaluate chromosomal abnormalities. Terms of the deal were not disclosed.
buyer: PerkinElmer, Inc. (PKI:$2,209.40)
PerkinElmer, Inc. is a global technology leader focused in the following businesses - Life and Analytical Sciences, Optoelectronics and Fluid Sciences. "
target: Spectral Genomics, Inc.
Spectral Genomics' array products and analysis software help pharmaceutical, biotechnology, cytogenetic and clinical researchers identify chromosomal abnormalities related to the study of cancer and pre- and post-natal genetic disorders.
price ($mm)
$12
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/23/2020 via BusinessWire

Curi Bio, acquired Dana Solutions

synopsis: Curi Bio has acquired Dana Solutions, a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays. They offer state-of-the-art AI products for drug screening, toxicity testing, and quality control.
buyer: Curi Bio
Curi Bio provides a seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines. "
target: Dana Solutions
Dana Solutions is a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays. They offer state-of-the-art AI products for drug screening, toxicity testing, and quality control.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/2/2020 via BusinessWire

Simulations Plus, Inc., acquired Lixoft

synopsis: Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, has acquired Lixoft of Paris, France. Lixoft designs software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development.
buyer: Simulations Plus, Inc. (SLP:$35.84)
Simulations Plus is a premier developer of drug discovery and development software and is a provider of preclinical and clinical pharmacometric consulting services for regulatory submissions. The company also provides quantitative systems pharmacology models for liver-related injury and disease. "
target: Lixoft
Paris-based Lixoft designs software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development. The company's Monolix Suite is a leading provider of population PKPD (Pharmacokinetic/Pharmacodynamic) modeling for pharmacometricians.
price ($mm)
$11
rev ($mm)
$4
EBITDA ($mm)
EV / rev
4.7x
EV / EBITDA
closed 9/13/2018 via BusinessWire

Certara, acquired Pirana Software

synopsis: Certara, the global leader in model-informed drug development, regulatory science, market access and real-world evidence solutions, announced that it has acquired Pirana, a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
buyer parent: Arsenal Capital Partners
buyer: Certara
Certara enables superior drug development and patient care decision-making through model-informed drug development, regulatory science, real-world evidence solutions and knowledge integration. "
target: Pirana Software
Pirana is a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/1/2017 via BusinessWire

Simulations Plus, Inc., acquired DILIsym Services, Inc.

synopsis: Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that it has acquired DILIsym Services, Inc, the leading provider of drug-induced liver injury simulation software and related consulting services to the pharmaceutical industry.
buyer: Simulations Plus, Inc. (SLP:$35.84)
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. "
target: DILIsym Services, Inc.
DILIsym Services, Inc. was founded in 2015 in Research Triangle Park, North Carolina, and is the leading provider of drug-induced liver injury simulation software and related consulting services to the pharmaceutical industry.
price ($mm)[EV]
$4.50 [$5.00]
rev ($mm)
$3
EBITDA ($mm)
EV / rev
3.3x
EV / EBITDA
closed 1/8/2013 via Yahoo, Inc.

Elsevier B.V., acquired Aureus Sciences

synopsis: Elsevier announced the acquisition of Aureus Sciences, a Paris, France based privately held company that provides databases and information tools to pharmaceutical and biotech companies. Aureus Sciences gathers unique and high quality quantitative biological activity data for major therapeutic drug targets.
buyer parent: Reed Elsevier
buyer: Elsevier B.V.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles. "
target: Aureus Sciences
Aureus Sciences provides scientific databases and software applications for researchers involved in the drug discovery and development process.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/2/2014 via BusinessWire

Cognigen Corporation merged with Simulations Plus, Inc.,

synopsis: Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that the Agreement and Plan of Merger with Cognigen Corporation has been closed. Cognigen Corporation was founded in 1993 and has grown to become one of the leading providers of clinical trial data analysis.
buyer: Simulations Plus, Inc. (SLP:$35.84)
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. "
target: Cognigen Corporation
Cognigen Corporation is one of the leading providers of clinical trial data analysis. The company provides analysis and reports that are tailored to the expectations of regulatory agencies so that reports are submitted in a manner that minimizes follow-up questions from regulators.
price ($mm)
$5.20
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 2/6/2014 via BNC Analysis

Berry Consultants, LLC, will purchase FACTS from Tessella Ltd.

synopsis: Berry Consultants, a statistical consulting company specializing in the Bayesian approach to medical statistics, has reached an agreement with Tessella to acquire 100% ownership of FACTS. FACTS (Fixed and Adaptive Clinical Trial Simulator) is the most powerful, versatile, and fastest clinical trial simulation tool on the market.
buyer: Berry Consultants, LLC
Berry Consultants is a statistical consulting company specializing in the Bayesian approach to medical statistics, an approach that is radically changing the way research is done throughout both device and drug development. "
seller: Tessella Ltd.
FACTS (Fixed and Adaptive Clinical Trial Simulator) is the most powerful, versatile, and fastest clinical trial simulation tool on the market. It allows biostatisticians and clinical teams to rapidly design and compare innovative, advanced, clinical trial designs.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/8/2014 via PR Newswire

Evidera, acquired Archimedes, Inc.

synopsis: Symphony Technology Group (STG), a technology and services-focused private equity firm, and Evidera, a leading provider of evidence-based solutions for the healthcare industry, announced the acquisition of Archimedes, a San Francisco-based healthcare modeling company and wholly owned subsidiary of Kaiser Permanente.
buyer parent: Symphony Technology Group
buyer: Evidera
Evidera provides health economics, outcomes research, market access, data analytics and epidemiology services. Their research and consulting services are driven by world-class science and thought leadership and leverage a unique combination of capabilities. "
target parent: Kaiser Permanente
target: Archimedes, Inc.
Archimedes is a healthcare modeling and analytics organization. With the Archimedes Model at its core, the company enables people to combine real-world healthcare data and simulation data to create compelling and actionable evidence used in individual healthcare decision making.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/27/2013 via PR Newswire

Temis Text Intelligence, acquired i3 Analytics

synopsis: TEMIS, the leading provider of Semantic Content Enrichment solutions for the Enterprise, announced that they have acquired the US-based i3 Analytics. i3 Analytics provides the award-winning Biopharma Navigator, a Software-as-a-Service platform that charts the biopharma landscape based on Life Sciences open data.
buyer: Temis Text Intelligence
In order to develop and market innovative Text Mining Solutions, TEMIS was founded in September 2000 by a team of managers, researchers and consultants from IBM. This skilled team had earlier developed and distributed IBM Text Mining solutions worldwide "
target: i3 Analytics
i3 Analytics is a provider of advanced data analytics and visualization technologies. Their Biopharma Navigator is an analytics tool that allow users to map clinical trials landscapes, scan the horizon for the latest news, and stay current on what researchers are doing.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/22/2009 via BusinessWire

Phase Forward, acquired Waban Software

synopsis: Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, announced that it has acquired privately held Waban Software, a leading provider of platform solutions for the automation and compliance of clinical data analysis and reporting, for $14 million in cash.
buyer: Phase Forward (PFWD:$0.00)
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture, clinical data management and clinical data analysis and reporting automation and compliance. "
target: Waban Software
Waban Software provides solutions that enable pharmaceutical and biotechnology companies to capture, integrate, manage and analyze life-sciences and clinical trial data.
price ($mm)
$12
rev ($mm)
$4
EBITDA ($mm)
EV / rev
3.5x
EV / EBITDA
closed 11/12/2008 via BusinessWire

JNetDirect, Inc., acquired Sunergia Group, Inc.

synopsis: JNetDirect Inc. announced the acquisition of Sunergia Group Inc. and its better known operating unit, Sunergia Medical (www.sunergiamedical.com). Sunergia, a privately owned supplier of software and lab equipment to the biotech market, will now be renamed JNetDirect Biosciences.
buyer: JNetDirect, Inc.
JNetDirect is an innovative leader in software products for improving our customer's connectivity, integration, management and security to their data resources. Over 3000 companies rely on JNetDirect software to provide critical components for their applications and development environments. "
target: Sunergia Group, Inc.
Founded in 2002, Sunergia has built a customer base that includes hundreds of the major university research labs, national research facilities (NIH, NIA, NIMH and NCI) and leading pharmaceutical and biotech companies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/25/2005 via BusinessWire

Phase Forward, acquired Lincoln Technologies, Inc.

synopsis: Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, announced that it has completed the previously announced acquisition of privately held Lincoln Technologies, Inc. in an all-cash transaction valued at $11 million, plus up to an additional $6 million based on achievement of certain financial targets.
buyer: Phase Forward (PFWD:$0.00)
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture, clinical data management and clinical data analysis and reporting automation and compliance. "
target: Lincoln Technologies, Inc.
Lincoln Technologies, Inc. is a software technology and services company that delivers advanced application solutions for pharmaceutical industry drug development. Lincoln's business is focused on pharmacovigilance, data standardization, and safety signal detection and monitoring.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like Vium, Inc.


read more

Vium, Inc.

Dana Solutions

Pirana Software

i3 Analytics

SCYNEXIS, Inc.

Envision Pharma, Inc.

Aris Global LLC

HEB LLC

Viedoc

Clinical Trial Connect, LLC

THREAD Research

OmniComm Systems, Inc.

Medidata

Custodix N.V.

GoBalto

Sylogent

Parallel 6

SecureConsent

Clinverse, Inc.

Medsight Solutions Inc.

read more

Vium, Inc.

read more

Vium, Inc.

read more

Vium, Inc.

Quantitative Medicine

Leadscope, Inc.

Adorial

Molegro

Simcyp Limited

Pharsight Corporation

Spectral Genomics, Inc.

Dana Solutions

Lixoft

Pirana Software

DILIsym Services, Inc.

Aureus Sciences

Cognigen Corporation

Tessella Ltd.

Archimedes, Inc.

i3 Analytics

Waban Software

Sunergia Group, Inc.

Lincoln Technologies, Inc.

Geography
Matching Companies
Ticker: SLP
 
 
 
 
 
 
 
 
Simulations Plus, Inc.
Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide.
year
2019
rev ($mm)
$35.84
EBITDA ($mm)
$12.38
EBIT ($mm)
$11.28
Net Income ($mm)
$9.11
Employees
109
  • drill down
  • watch
Ticker: POAI
 
 
 
 
 
 
 
 
Predictive Oncology Inc.
Predictive Oncology Inc.
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
year
2019
rev ($mm)
$1.38
EBITDA ($mm)
($13.26)
EBIT ($mm)
($13.71)
Net Income ($mm)
Employees
24
  • drill down
  • watch
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: ZMD
 
 
 
 
 
 
 
 
ZoomMed Inc.
ZoomMed Inc.
Zoommed Inc. develops and markets various computer applications for healthcare professionals in Canada. The company builds and operates the ZoomMed Communication Network, a clinical interoperable information exchange network between physicians and various other stakeholders of the healthcare sector.
year
2014
rev ($mm)
$6.08
EBITDA ($mm)
$2.65
EBIT ($mm)
$2.78
Net Income ($mm)
Employees
40
  • drill down
  • watch
Ticker: ASX:MDR
 
 
 
 
 
 
 
 
MedAdvisor Limited
MedAdvisor Limited
MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. The highly automated Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records.
year
2016
rev ($mm)
$1.05
EBITDA ($mm)
($2.13)
EBIT ($mm)
($2.15)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: SLP
 
 
 
 
 
 
 
 
Simulations Plus, Inc.
Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide.
year
2019
rev ($mm)
$35.84
EBITDA ($mm)
$12.38
EBIT ($mm)
$11.28
Net Income ($mm)
$9.11
Employees
109
  • drill down
  • watch
Ticker: POAI
 
 
 
 
 
 
 
 
Predictive Oncology Inc.
Predictive Oncology Inc.
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
year
2019
rev ($mm)
$1.38
EBITDA ($mm)
($13.26)
EBIT ($mm)
($13.71)
Net Income ($mm)
Employees
24
  • drill down
  • watch
Ticker: DATA
 
 
 
 
 
 
 
 
DATATRAK International, Inc.
DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(TM) and related services to the pharmaceutical, biotechnology, and medical device industries.
year
2012
rev ($mm)
$9.72
EBITDA ($mm)
($1.37)
EBIT ($mm)
($1.53)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: AIM:INS
 
 
 
 
 
 
 
 
Instem
Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide.
year
2019
rev ($mm)
$30.83
EBITDA ($mm)
$4.12
EBIT ($mm)
$3.15
Net Income ($mm)
$2.27
Employees
238
  • drill down
  • watch
Ticker: OMCL
 
 
 
 
 
 
 
 
Omnicell, Inc.
Omnicell, Inc.
Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.
year
2016
rev ($mm)
$692.62
EBITDA ($mm)
$62.94
EBIT ($mm)
$16.58
Net Income ($mm)
$0.60
Employees
2444
  • drill down
  • watch
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: ZMD
 
 
 
 
 
 
 
 
ZoomMed Inc.
ZoomMed Inc.
Zoommed Inc. develops and markets various computer applications for healthcare professionals in Canada. The company builds and operates the ZoomMed Communication Network, a clinical interoperable information exchange network between physicians and various other stakeholders of the healthcare sector.
year
2014
rev ($mm)
$6.08
EBITDA ($mm)
$2.65
EBIT ($mm)
$2.78
Net Income ($mm)
Employees
40
  • drill down
  • watch
Ticker: ASX:MDR
 
 
 
 
 
 
 
 
MedAdvisor Limited
MedAdvisor Limited
MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. The highly automated Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records.
year
2016
rev ($mm)
$1.05
EBITDA ($mm)
($2.13)
EBIT ($mm)
($2.15)
Net Income ($mm)
Employees
  • drill down
  • watch